Clinical trials: Pyelonephritis Acute
Urinary Tract Infection, Fever
Treatment's Duration of Acute Uncomplicated Pyelonephritis
The purpose of this study is to compare the efficacy of 5 days versus 10 days treatment duration in uncomplicated acute pyelonephritis.
- Trial name
- DTP (NCT00873626)
- Testing
- levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
- Where
- 2 sites in France
- Volunteers
- 310 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Complicated Urinary Tract Infection Including Acute Pyelonephritis
Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
This is A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/Funobactam in Comparison with Meropenem in Hospitalized Adults with…
- Trial name
- NCT05204368
- Testing
- Combination of Imipenem/Cilastatin and XNW4107, Meropenem
- Where
- United States
- Volunteers
- 780 people
- Sponsor
- Evopoint Biosciences Inc.
Urolithiasis, Urologic Diseases
Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis
To investigate the effectiveness of percutaneous nephrostomy catheter placement versus retrograde double J catheter placement in patients with symptoms of obstructive kidney disease (with either infection and/or pain and/or…
- Conditions
- Urolithiasis, Urologic Diseases, Urinary Calculi, Urinary Obstruction
- Trial name
- STONE (NCT04594161)
- Testing
- Percutaneous Nephrostomy, Double J catheter
- Where
- Netherlands
- Volunteers
- 204 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Urinary Tract Infections, Pyelonephritis
NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis
The goal of this clinical study is to test NRX101 in participants with complicated urinary tract infections including pyelonephritis.
- Trial name
- NCT06128213
- Testing
- NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))
- Volunteers
- 13 people
- Sponsor
- NeuroRx, Inc.
Acute Pyelonephritis
Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis
The aim of this study is to investigate the diagnostic and prognostic value of C-reactive protein (CRP), serum procalcitonin (PCT) and soluble urokinase plasminogen activator receptor (suPAR) in the initial investigation of…
- Trial name
- NCT04686318
- Testing
- Biomarkers for acute pyelonephritis
- Where
- Denmark
- Volunteers
- 229 people
- Sponsor
- University of Southern Denmark
Acute Pyelonephritis(APN)
L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis
Risk factors for parenchymal damage in urinary tract infection are vesicoureteral reflux (VUR),obstructive uropathy,the number of flares of acute pyelonephritis(APN) and delay in treatment of acute infection.The pathogenesis of…
- Trial name
- NCT02007889
- Testing
- L-carnitine
- Where
- Iran
- Volunteers
- 78 people
- Sponsor
- Shahid Beheshti University
Pyelonephritis
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Temocillin, a 6-alpha-methoxypenicillin derivative of ticarcillin, is a narrow-spectrum antibiotic, primarily restricted to Enterobacterales.
- Trial name
- TEMOKID-POP (NCT07070102)
- Testing
- blood samples
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pyelonephritis
Effect of Acetylcysteine in Pediatric Acute Pyelonephritis.
In different studies, it has been shown that "antioxidant" utilization has favorable therapeutic effects not only on control of acute symptoms but also on prevention of delayed problems from acute and chronic pyelonephritis.
- Trial name
- NCT02080182
- Testing
- Acetylcysteine
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Pyelonephritis
Prospective Study in the Emergency
The prevalence of acute pyelonephritis (PNA) is 60-75 000/year. They are traditionally classified as uncomplicated (60-65%) and complicated.
- Trial name
- PROPA (NCT01628900)
- Testing
- care management arm N°1 vs arm N°2, Care management
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Complicated Urinary Tract Infection, Acute Pyelonephritis
Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
Sulopenem etzadroxil/probenecid is available to clinicians through an Expanded Access Program for the treatment of complicated urinary tract infections due to quinolone nonsusceptible uropathogens after an initial course of…
- Trial name
- NCT04682834
- Testing
- Sulopenem Etzadroxil/Probenecid
- Sponsor
- Iterum Therapeutics, International Limited
Complicated Urinary Tract Infection, Acute Pyelonephritis
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of IV ETX2514SUL in patients with complicated urinary tract infections (cUTIs) who are otherwise relatively healthy.
- Trial name
- NCT03445195
- Testing
- Sulbactam-ETX2514, Imipenem-cilastatin
- Where
- 4 sites in Bulgaria
- Volunteers
- 80 people
- Sponsor
- Entasis Therapeutics
Urinary Tract Infection, Acute Pyelonephritis
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication)…
- Trial name
- PIVOT-PO (NCT06059846)
- Testing
- TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 1,690 people
- Sponsor
- Spero Therapeutics
Pyelonephritis Acute
Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis
This pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (PDAD).
- Trial name
- NCT06127160
- Testing
- Cephalexin
- Where
- 2 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Brett A Faine
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis
- Trial name
- NCT01595438
- Testing
- Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
- Where
- 80 sites in United States, Argentina and 20 more
- Volunteers
- 598 people
- Sponsor
- Pfizer
Urinary Tract Infections
Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI
Phase 2, randomised, double-blind, 2-cohort study in hospitalised adults with complicated urinary tract infection (cUTI), including acute pyelonephritis. All study cohorts were randomised in a 2:1 ratio.
- Trial name
- NCT03680612
- Testing
- Cefepime 1G - 2G / AAI101 0.5G - 0.75G, cefepime 1 g or cefepime 2 g
- Where
- 5 sites in Czechia, Hungary and 3 more
- Volunteers
- 45 people
- Sponsor
- Allecra
Acute Uncomplicated Pyelonephritis
Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin
The purpose of the study is to compare the safety and effectiveness of the antibiotic levofloxacin by administering a higher dose of levofloxacin using a shorter course of therapy to treat patients with infections of their kidney.
- Trial name
- NCT00239161
- Testing
- Levofloxacin
- Where
- 4 sites in Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Pyelonephritis
Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis
Pyelonephritis is a serious infection that manifests with fever, back pain, nausea, and vomiting. In the U.S., it is estimated that there are 20 cases of pyelonephritis per 10,000 annually, with the highest incidence in young…
- Trial name
- NCT01641029
- Testing
- No intervention
- Where
- United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Olive View-UCLA Education & Research Institute
Acute Pyelonephritis(APN)
Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children
Urinary tract infections (UTI) are a common and important clinical problem in childhood.Upper urinary tract infections (ie, acute pyelonephritis) may lead to renal scarring, hypertension, and end-stage renal disease.Pathogenesis…
- Trial name
- NCT02192580
- Testing
- Omega-3
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Shahid Beheshti University
Complicated Urinary Tract Infection, Acute Pyelonephritis
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
Phase 2, randomised, double-blind,double-dummy study in hospitalised adults with complicated urinary tract infection (cUTI), including acute pyelonephritis.Treatment duration for each cohort was 7 to 14 days.
- Trial name
- NCT05060419
- Testing
- Meropenem- FL058, Piperacillin -tazobactam, Saline
- Volunteers
- 150 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.